Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ARAV NASDAQ:ARCT NASDAQ:CRVS NASDAQ:HROW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.90-1.2%$5.37$1.14▼$7.20$297.08M0.8754,609 shs845,889 shsARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AARCTArcturus Therapeutics$18.05-0.2%$15.62$8.04▼$25.88$491.23M2.39472,170 shs581,928 shsCRVSCorvus Pharmaceuticals$5.79+0.9%$5.00$2.54▼$10.00$427.71M0.52543,267 shs414,586 shsHROWHarrow$43.15+0.6%$36.81$20.85▼$59.23$1.59B0.33492,381 shs611,140 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-2.55%-13.89%-7.98%+56.47%-16.07%ARAVARAVIVE0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics-0.22%+0.84%-7.14%+46.48%-12.23%CRVSCorvus Pharmaceuticals-2.38%-6.97%+5.71%+46.06%-0.69%HROWHarrow+0.14%+9.11%+10.46%+36.04%-2.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.90-1.2%$5.37$1.14▼$7.20$297.08M0.8754,609 shs845,889 shsARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AARCTArcturus Therapeutics$18.05-0.2%$15.62$8.04▼$25.88$491.23M2.39472,170 shs581,928 shsCRVSCorvus Pharmaceuticals$5.79+0.9%$5.00$2.54▼$10.00$427.71M0.52543,267 shs414,586 shsHROWHarrow$43.15+0.6%$36.81$20.85▼$59.23$1.59B0.33492,381 shs611,140 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-2.55%-13.89%-7.98%+56.47%-16.07%ARAVARAVIVE0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics-0.22%+0.84%-7.14%+46.48%-12.23%CRVSCorvus Pharmaceuticals-2.38%-6.97%+5.71%+46.06%-0.69%HROWHarrow+0.14%+9.11%+10.46%+36.04%-2.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.67Moderate Buy$9.5093.88% UpsideARAVARAVIVE 0.00N/AN/AN/AARCTArcturus Therapeutics 3.00Buy$50.57180.17% UpsideCRVSCorvus Pharmaceuticals 3.00Buy$13.00124.53% UpsideHROWHarrow 2.88Moderate Buy$64.6749.86% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, ALDX, CRVS, ARAV, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $63.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $64.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.008/8/2025ALDXAldeyra TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$76.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$1.19 per shareN/AARAVARAVIVE$9.14MN/AN/AN/AN/AN/AARCTArcturus Therapeutics$152.31M3.22N/AN/A$8.90 per share2.03CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AHROWHarrow$199.61M8.00$0.14 per share313.62$1.95 per share22.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$55.85M-$0.85N/AN/AN/AN/A-73.63%-50.61%11/6/2025 (Estimated)ARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/AARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)CRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)HROWHarrow-$17.48M-$0.25N/A107.88N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)Latest ARCT, ALDX, CRVS, ARAV, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025ALDXAldeyra Therapeutics-$0.21-$0.16+$0.05-$0.16$1.08 millionN/A8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AARAVARAVIVEN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.862.86ARAVARAVIVEN/AN/AN/AARCTArcturus TherapeuticsN/A5.905.90CRVSCorvus PharmaceuticalsN/A8.918.91HROWHarrow0.780.620.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ARAVARAVIVE35.80%ARCTArcturus Therapeutics94.54%CRVSCorvus Pharmaceuticals46.64%HROWHarrow72.76%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%ARAVARAVIVE60.40%ARCTArcturus Therapeutics16.60%CRVSCorvus Pharmaceuticals28.50%HROWHarrow15.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1059.90 million54.15 millionOptionableARAVARAVIVE20N/AN/ANo DataARCTArcturus Therapeutics18027.16 million22.65 millionOptionableCRVSCorvus Pharmaceuticals3074.51 million53.28 millionOptionableHROWHarrow18037.00 million31.39 millionOptionableARCT, ALDX, CRVS, ARAV, and HROW HeadlinesRecent News About These CompaniesVoya Investment Management LLC Boosts Stock Position in Harrow, Inc. $HROWSeptember 17 at 3:26 AM | marketbeat.comHarrow Health (HROW) Receives a Buy from Lake StreetSeptember 16 at 10:29 PM | theglobeandmail.comHarrow (NASDAQ:HROW) Trading 7.3% Higher - Here's WhySeptember 16 at 8:20 PM | marketbeat.comHarrow Announces Agenda and Speakers for Investor & Analyst DaySeptember 15 at 7:00 AM | globenewswire.comWilliam Blair Analysts Lower Earnings Estimates for HarrowSeptember 13, 2025 | marketbeat.comWilliam Blair Issues Negative Estimate for Harrow EarningsSeptember 13, 2025 | americanbankingnews.comHarrow Health Completes $250M Senior Notes SaleSeptember 12, 2025 | tipranks.comHarrow: Buy A Blend Of Value And GrowthSeptember 12, 2025 | seekingalpha.comTrexquant Investment LP Sells 84,853 Shares of Harrow, Inc. $HROWSeptember 12, 2025 | marketbeat.comReviewing Harrow (NASDAQ:HROW) and Ernexa Therapeutics (NASDAQ:ERNA)September 11, 2025 | americanbankingnews.comReviewing Miravant Medical Technologies (OTCMKTS:MRVT) and Harrow (NASDAQ:HROW)September 11, 2025 | americanbankingnews.comHarrow (HROW) Launches US$250M Senior Notes Offering To Refinance DebtSeptember 11, 2025 | finance.yahoo.comHarrow (NASDAQ:HROW) Shares Gap Up - Here's WhySeptember 10, 2025 | marketbeat.comHarrow: A Classical GARP StockSeptember 9, 2025 | seekingalpha.comHarrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030September 8, 2025 | globenewswire.comHarrow launches $250M debt offeringSeptember 8, 2025 | msn.comHarrow Health Launches $250 Million Senior Notes OfferingSeptember 8, 2025 | msn.comHarrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030September 8, 2025 | globenewswire.comAmerican Century Companies Inc. Purchases 18,142 Shares of Harrow, Inc. $HROWSeptember 6, 2025 | marketbeat.comHarrow Health’s Earnings Call Highlights Growth and ChallengesSeptember 5, 2025 | theglobeandmail.comHarrow, Inc. $HROW Shares Acquired by Braidwell LPSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, ALDX, CRVS, ARAV, and HROW Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$4.90 -0.06 (-1.21%) Closing price 04:00 PM EasternExtended Trading$4.91 +0.01 (+0.20%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.ARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 09/16/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Arcturus Therapeutics NASDAQ:ARCT$18.05 -0.04 (-0.22%) Closing price 04:00 PM EasternExtended Trading$18.24 +0.18 (+1.02%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Corvus Pharmaceuticals NASDAQ:CRVS$5.79 +0.05 (+0.87%) Closing price 04:00 PM EasternExtended Trading$5.85 +0.06 (+1.04%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Harrow NASDAQ:HROW$43.15 +0.27 (+0.63%) Closing price 04:00 PM EasternExtended Trading$43.78 +0.63 (+1.47%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
